The role of optic nerve blood flow in the pathogenesis of glaucoma

Alon Harris, Ehud Rechtman, Brent Siesky, Christian Jonescu-Cuypers, Lynne McCranor, Hana J. Garzozi

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Although IOP reduction remains the primary goal of POAG therapy, increasing evidence shows that other considerations, including vascular factors leading to ischemia, may contribute to disease initiation or progression. At present, we lack longitudinal, prospective, and randomized trials regarding the effect of ocular blood flow on POAG prognosis. If such studies show a protective effect against POAG, they will open a new era in glaucoma management.

Original languageEnglish
Pages (from-to)345-353
Number of pages9
JournalOphthalmology Clinics of North America
Volume18
Issue number3
DOIs
StatePublished - Sep 2005

Fingerprint

Optic Nerve
Glaucoma
Ischemia
Therapeutics
vascular factor

ASJC Scopus subject areas

  • Ophthalmology

Cite this

The role of optic nerve blood flow in the pathogenesis of glaucoma. / Harris, Alon; Rechtman, Ehud; Siesky, Brent; Jonescu-Cuypers, Christian; McCranor, Lynne; Garzozi, Hana J.

In: Ophthalmology Clinics of North America, Vol. 18, No. 3, 09.2005, p. 345-353.

Research output: Contribution to journalArticle

Harris, Alon ; Rechtman, Ehud ; Siesky, Brent ; Jonescu-Cuypers, Christian ; McCranor, Lynne ; Garzozi, Hana J. / The role of optic nerve blood flow in the pathogenesis of glaucoma. In: Ophthalmology Clinics of North America. 2005 ; Vol. 18, No. 3. pp. 345-353.
@article{1f17052fb50949d4a7820b36e5630e84,
title = "The role of optic nerve blood flow in the pathogenesis of glaucoma",
abstract = "Although IOP reduction remains the primary goal of POAG therapy, increasing evidence shows that other considerations, including vascular factors leading to ischemia, may contribute to disease initiation or progression. At present, we lack longitudinal, prospective, and randomized trials regarding the effect of ocular blood flow on POAG prognosis. If such studies show a protective effect against POAG, they will open a new era in glaucoma management.",
author = "Alon Harris and Ehud Rechtman and Brent Siesky and Christian Jonescu-Cuypers and Lynne McCranor and Garzozi, {Hana J.}",
year = "2005",
month = "9",
doi = "10.1016/j.ohc.2005.04.001",
language = "English",
volume = "18",
pages = "345--353",
journal = "Ophthalmology Clinics of North America",
issn = "0896-1549",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - The role of optic nerve blood flow in the pathogenesis of glaucoma

AU - Harris, Alon

AU - Rechtman, Ehud

AU - Siesky, Brent

AU - Jonescu-Cuypers, Christian

AU - McCranor, Lynne

AU - Garzozi, Hana J.

PY - 2005/9

Y1 - 2005/9

N2 - Although IOP reduction remains the primary goal of POAG therapy, increasing evidence shows that other considerations, including vascular factors leading to ischemia, may contribute to disease initiation or progression. At present, we lack longitudinal, prospective, and randomized trials regarding the effect of ocular blood flow on POAG prognosis. If such studies show a protective effect against POAG, they will open a new era in glaucoma management.

AB - Although IOP reduction remains the primary goal of POAG therapy, increasing evidence shows that other considerations, including vascular factors leading to ischemia, may contribute to disease initiation or progression. At present, we lack longitudinal, prospective, and randomized trials regarding the effect of ocular blood flow on POAG prognosis. If such studies show a protective effect against POAG, they will open a new era in glaucoma management.

UR - http://www.scopus.com/inward/record.url?scp=23044436202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23044436202&partnerID=8YFLogxK

U2 - 10.1016/j.ohc.2005.04.001

DO - 10.1016/j.ohc.2005.04.001

M3 - Article

C2 - 16054992

AN - SCOPUS:23044436202

VL - 18

SP - 345

EP - 353

JO - Ophthalmology Clinics of North America

JF - Ophthalmology Clinics of North America

SN - 0896-1549

IS - 3

ER -